Ovid Therapeutics Inc. (OVID)
OVIDNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.87
+0.0900 (+3.24%) today
Regular session, Nov 11, 4:00 PM ET
- Market cap
- $521.45m
- P/E
- –
- EPS, last 4 quarters
- $-0.2400
- Dividend yield
- –
- Day range
- $2.66 to $2.86
- 52-week range
- $1.18 to $3.11
- Average volume
- 1.94m
- Previous close
- $2.78
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $6.50, +126.5% from here
Earnings
next estimate $-0.0800Next report
Dec 2025
+160.0%
Mar 2026
0.0%
Jun 2026
+20.0%
Sep 2026
-25.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $132.0k | $718.0k | – | $733.0k |
| Gross profit | $132.0k | $718.0k | – | $733.0k |
| Operating income | -$12.52m | -$12.29m | -$17.85m | -$15.70m |
| Net income | -$12.16m | $9.66m | -$16.99m | -$15.01m |
News
8 latest- Ovid Therapeutics Reports Q3 Results; Multiple Pipeline Readouts Expected In 2027 RTTNews · 1 day ago
- Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue EstimatesZacks · 6 days ago
- Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue EstimatesZacks · 7 days ago
- Cantor Fitzgerald Initiates Coverage of Ovid Therapeutics with Overweight RatingFintel · Oct 9, 2026
- After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data RTTNews · Aug 20, 2026
- What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?Zacks · Aug 18, 2026
- Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Aug 6, 2026
- Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue EstimatesZacks · Aug 6, 2026
The company
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The Company discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with great unmet need. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant FOS and DEEs, including TSC and IS; and OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- ovidrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.